Bisphosphonate Drug Market Report 2026

The bisphosphonate drug market size has grown strongly in recent years. It will grow from $5.28 billion in 2025 to $5.61 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to osteoporosis prevalence, aging population, hospital bone care protocols, fracture prevention programs, oral bisphosphonate adoption.

The bisphosphonate drug market size is expected to see strong growth in the next few years. It will grow to $7.04 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to geriatric population growth, injectable therapy adoption, oncology supportive care, generic drug expansion, preventive bone health focus. Major trends in the forecast period include increased use in postmenopausal osteoporosis, shift toward injectable long-acting formulations, growth of generic bisphosphonate drugs, expansion of cancer-related bone loss treatment, focus on fracture risk reduction.

The increasing prevalence of osteoporosis is expected to drive the growth of the bisphosphonates drug market going forward. Osteoporosis is a condition characterized by weakened bones that are more susceptible to fractures due to reduced bone density. Its prevalence is rising mainly because of the aging global population, as bone density naturally declines with age, compounded by lifestyle factors and limited preventive care. Bisphosphonate drugs help treat osteoporosis by slowing bone breakdown, thereby strengthening bones and reducing fracture risk. For instance, in August 2024, according to Healthy Bones Australia, an Australia-based organization focused on bone health research and advocacy, there were an estimated 193,482 osteoporosis- and osteopenia-related fractures in 2023, projected to increase by 34% to 237,632 fractures by 2033. Therefore, the increasing prevalence of osteoporosis is driving the growth of the bisphosphonates drug market.

Major companies operating in the bisphosphonate drug market are focusing on obtaining regulatory approvals to expand product reach, enhance market competitiveness, and ensure compliance with evolving safety and efficacy standards. Regulatory approvals are official permissions from government health agencies allowing companies to sell and market drugs after demonstrating safety and effectiveness. For instance, in March 2025, Celltrion, Inc., a South Korea-based biopharmaceutical company, received U.S. FDA approval for its biosimilars STOBOCLO (denosumab-bmwo) and OSENVELT (denosumab-bmwo). STOBOCLO is indicated for osteoporosis-related conditions, including treatment of postmenopausal women and men with osteoporosis, glucocorticoid-induced osteoporosis, and bone loss in patients undergoing certain cancer therapies. OSENVELT is approved for cancer-related skeletal events, such as prevention of bone complications in patients with multiple myeloma or bone metastases, treatment of giant cell tumor of bone, and management of hypercalcemia of malignancy.

In May 2023, Abiogen Pharma S.p.A., an Italy-based pharmaceutical company, acquired EffRx Pharmaceuticals SA for an undisclosed amount. This acquisition enables Abiogen to strengthen and diversify its rare disease portfolio by integrating EffRx’s innovative musculoskeletal and rare-disease treatments, while expanding Abiogen’s international presence and capabilities in developing and commercializing specialized therapies worldwide. EffRx Pharmaceuticals SA, based in Switzerland, manufactures and commercializes bisphosphonate drugs for treating osteoporosis.

Major companies operating in the bisphosphonate drug market are Mylan N.V., Sandoz International GmbH, Fresenius Kabi AG, Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Cadila Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Micro Labs Ltd., Wockhardt Ltd., Macleods Pharmaceuticals Ltd., Emcure Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Granules India Ltd., IPCA Laboratories Ltd., Jubilant Pharmova Ltd., Accord Healthcare Ltd., Aarti Drugs Ltd., Shilpa Medicare Ltd., Indoco Remedies Ltd., Unichem Laboratories Ltd., Alvogen Inc., Perrigo Company plc, ANI Pharmaceuticals Inc., Endo International plc.

North America was the largest region in the bisphosphonate drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bisphosphonate drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bisphosphonate drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the bisphosphonate drug market by increasing costs for active pharmaceutical ingredients, injectable formulations, and sterile packaging materials. Zoledronic acid and intravenous bisphosphonate segments are most affected, especially in North America and Europe due to global sourcing of oncology and osteoporosis drugs. Positively, tariffs are driving local manufacturing of generic bisphosphonates, improving affordability and supply continuity.

The bisphosphonate drug market research report is one of a series of new reports that provides bisphosphonate drug market statistics, including bisphosphonate drug industry global market size, regional shares, competitors with a bisphosphonate drug market share, detailed bisphosphonate drug market segments, market trends and opportunities, and any further data you may need to thrive in the bisphosphonate drug industry. This bisphosphonate drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bisphosphonates are a class of drugs that help prevent the loss of bone density. They are commonly used to treat or prevent osteoporosis and other bone-related conditions by slowing the process of bone breakdown. The primary goal of bisphosphonates is to strengthen bones and reduce the risk of fractures, particularly in individuals with osteoporosis.

The main types of bisphosphonate drugs include alendronate, risedronate, and zoledronic acid. Alendronate is a bisphosphonate used to treat and prevent osteoporosis by reducing bone loss and increasing bone density. These medications are administered orally or intravenously and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels. They are applied in conditions such as postmenopausal osteoporosis, osteoporosis in men, Paget’s disease, bone loss from cancer treatment, glucocorticoid-induced osteoporosis, and others, serving end-users including hospitals, clinics, homecare settings, and more.

The bisphosphonate drug market consists of sales of products including oral tablets, bisphosphonate capsules, bisphosphonate injections, oral solutions, and intravenous (IV) infusions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.